Skip to main content

Month: July 2023

Solid Power Appoints Two New Directors to the Board, Adding Financial, Human Resources, and Information Technology Expertise

Kaled Awada brings global leadership and human resources expertise Susan Kreh brings financial and information technology expertiseLOUISVILLE, Colo., July 10, 2023 (GLOBE NEWSWIRE) — Solid Power, Inc. (“Solid Power”) (Nasdaq: SLDP), a developer of solid state battery technology, today announced two new appointments to its board of directors: Kaled Awada, a C-level leader in global human resource management, and Susan Kreh, a C-level executive with more than 35 years of finance and information technology leadership. The two joined Solid Power’s board of directors effective July 5, 2023. “Kaled and Susan bring to Solid Power extensive leadership experience in their respective fields, and will provide valuable guidance as Solid Power continues to grow and execute on its strategy,” said Dave Jansen, Chairperson of Solid...

Continue reading

Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors

Enrollment progressing toward interim analysis planned when 36 subjects reach 12 weeks on treatment in Part 1 of study BOSTON and LONDON, July 10, 2023 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced the dosing of the first subject in its registrational PRESent-2 study of SerpinPC for the treatment of hemophilia B without inhibitors. The dosing phase of PRESent-2 follows a minimum 12-week observation period during which prospective baseline data of the subject’s disease status under their current therapy are collected to support regulatory review of the benefit and risk profile of SerpinPC. SerpinPC is an investigational subcutaneously administered novel inhibitor of activated...

Continue reading

Westerwood Global to Rebrand as WGNSTAR Following Acquisition of NSTAR

Unveiling New Solutions for Advanced Workforce and Asset Lifecycle Management DUBLIN, Ireland and GARNER, N.C., July 10, 2023 (GLOBE NEWSWIRE) — Westerwood Global, a leading provider of managed service solutions, today announced its transformation and rebranding as WGNSTAR, following the acquisition of NSTAR® Global Services (NSTAR), a renowned leader in facility and equipment services and workforce management. This strategic move will leverage the powerful synergies between the two organizations and provide a more unified global infrastructure. “We are thrilled to announce the coming together of Westerwood Global and NSTAR under the singular WGNSTAR brand. This strategic move marks a significant milestone for our company, solidifying our commitment to our combined teams as well as to future growth, innovation, and delivering exceptional...

Continue reading

Global Multi-effects Processor Market is Expected to Record a CAGR of 5.9% From 2023 To 2032 – Latest Industry Insights by Esticast Research & Consulting

According to experts from Esticast Research, the growth of the market is being propelled by technological advancements, particularly the adoption of digital signal processing (DSP) technology. Esticast Research, July 10, 2023 (GLOBE NEWSWIRE) — Pune, India 10th July 2023, Multi-effects Processor Market -Growth Factors and Dynamics The Multi-effects Processor market is segmented By type (Reverb Effect, Delay Effect, and Others) and By Application (Beginner and Professional), By Region, And Segment Forecasts, 2023 – 2032Attributes ValueMulti-effects Processor Market Expected Value (2023) USD 270.55 millionMulti-effects Processor Market Forecast Value (2032) USD 337.86 millionMulti-effects Processor Market Expected CAGR (2023 to 2032) 5.9%Click Here to Access a Free Sample Report ON Global Multi-Effects Processor Market https://www.esticastresearch.com/request-a-sample/37526The...

Continue reading

Panbela Announces Preliminary Safety Analysis for ASPIRE Trial

MMINNEAPOLIS, July 10, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announces that the independent Data Safety Monitoring Board (DSMB) of the Phase III ASPIRE clinical trial for patients with untreated metastatic pancreatic ductal adenocarcinoma has completed its pre-specified review of safety data for treated patients in the trial. The DSMB has recommended that the study continue without modification. The ASPIRE Trial is a global randomized, double-blind placebo-controlled clinical trial to evaluate ivospemin in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. “We are pleased that no safety concerns were identified and the DSMB’s...

Continue reading

Xometry Further Expands Offerings On Its AI-Powered Marketplace

Xometry Instant Quoting Engine® Now Supports Inserts, Multi-Part Assemblies And Expanded Sheet-Cutting Processes Enhancements Further Accelerate Xometry’s Assembly Production Work Proprietary AI Technology Learns From Every Interaction, Enabling Xometry To Continuously Evaluate, Build And Roll Out New Products Delivering Instant Pricing And Lead Times For Ever-Expansive Universe Of PartsNORTH BETHESDA, Md., July 10, 2023 (GLOBE NEWSWIRE) — Xometry, the global AI-driven marketplace connecting enterprise buyers with suppliers of manufacturing services, today announced the continued expansion of its AI-powered Xometry Instant Quoting Engine® to include instant-quoting of inserts, multi-part assemblies, and expanded sheet-cutting processes. The enhanced features allow buyers to instantly get pricing and lead times on CNC, sheet...

Continue reading

MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies

MaxCyte’s Flow Electroporation® technology and ExPERT™ platform will support Vittoria’s Senza5™ technology to enhance efficacy and improve clinical utility of T-cell therapies. ROCKVILLE, Md. and PHILADELPHIA, July 10, 2023 (GLOBE NEWSWIRE) — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, and Vittoria Biotherapeutics (Vittoria), a leading edge, gene-edited cell therapeutics company with novel platform technologies poised to develop a pipeline of highly differentiated cellular therapies for both oncology and immunology indications, today announced the signing of a strategic platform license...

Continue reading

AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions

Preliminary Ampligen data demonstrates potential to be an effective treatment option for post-COVID conditions Enrollment expected to be completed in Q4 2023 OCALA, Fla., July 10, 2023 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced it has enrolled and dosed the first subject in the company’s Phase 2 study evaluating Ampligen® as a potential therapeutic for people with post-COVID conditions (“AMP-518”). This important study milestone follows on the heels of the company having recently opened multiple clinical study sites and having screened numerous subjects. Study screening is ongoing and AIM expects to dose additional new subjects in the coming weeks. For more information about AMP-518, please visit ClinicalTrials.gov and reference identifier NCT05592418. AIM Chief Executive Officer Thomas...

Continue reading

BIO-key Customers in Florida and Illinois Migrate Their Identity and Access Management to the Cloud with PortalGuard® IDaaS

WALL, N.J., July 10, 2023 (GLOBE NEWSWIRE) — BIO-key International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB), announced that existing customers West Aurora School District 129 in Aurora, IL and Gulf Coast State College in Panama City, FL are migrating to BIO-key’s PortalGuard® IDaaS cloud-based identity management solution, a significant step in modernizing their IAM capabilities. By adopting IDaaS, West Aurora and Gulf Coast can centralize and streamline their identity management processes while taking advantage of cloud scalability, flexibility, and security while providing an enhanced user experience – all with improved administrative capabilities. In today’s digital landscape, where secure access...

Continue reading

TerrAscend Reaches Four Dispensary Cap in Maryland with Closing of Herbiculture Acquisition

Acquisition expected to be immediately accretive on an EBITDA and cashflow basis TORONTO, July 10, 2023 (GLOBE NEWSWIRE) — TerrAscend Corp. (“TerrAscend” or the “Company”) (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis company, today announced the closing of its previously announced acquisition of Herbiculture Inc. (d/b/a “Herbiculture”), a medical dispensary in Maryland. With this transaction, TerrAscend has reached the four dispensary cap in the state. With the recent launch of adult-use sales in Maryland on July 1, 2023, the Company believes that Herbiculture is well positioned to achieve substantial sales and profit growth. This transaction is expected to be immediately accretive to TerrAscend on an EBITDA and cashflow basis. Located in an approximately 3,100 square foot location in Burtonsville, Herbiculture...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.